# US 9,750,776 B2 · Agents for promoting secretion and/or suppressing decrease of adiponectin > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 9,750,776 B2 - Document ID: US9750776B2 - Status: Granted - Kind: B2 - Application number: 12/920,844 - Filed: 2009-03-09 - Published: 2011-01-27 - Granted: 2017-09-05 - Earliest claimed: 2008-03-07 - Assignees: Megmilk Snow Brand Co., Ltd.; Savencia SA - Applicants: Yukiko Kunieda; Tomohiro Hosoya; Shun Obuchi; Tsuguaki Nishiya; Joelle Reitz; Christine Martin Rouas; Remi Perrin; Philippe Marchal - Inventors: Yukiko Kunieda; Tomohiro Hosoya; Shun Obuchi; Tsuguaki Nishiya; Joelle Reitz; Christine Martin Rouas; Remi Perrin; Philippe Marchal - Web page: https://patentgrep.com/patent/US9750776B2 ## CPC - A61K 36/06: Fungi, e.g. yeasts - A23K 10/18: of live microorganisms - A23K 50/40: for carnivorous animals, e.g. cats or dogs - A23L 33/135: Bacteria or derivatives thereof, e.g. probiotics - A61K 35/744: Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs - A61K 35/747: Lactobacilli, e.g. L. acidophilus or L. brevis - A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00) - A61P 3/04: Anorexiants; Antiobesity agents - A61P 3/06: Antihyperlipidemics - A61P 3/10: for hyperglycaemia, e.g. antidiabetics - A61P 9/12: Antihypertensives - A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A23K: FODDER - A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract To provide an agent promoting secretion and/or suppressing decrease of adiponectin, and an eating and drinking product and a feed promoting secretion and/or suppressing decrease of adiponectin. Provided are an agent promoting secretion and/or suppressing decrease of adiponectin, and a eating and drinking product and a feed promoting secretion and/or suppressing decrease of adiponectin, having as an active component a culture supernatant of Streptococcus, Lactobacillus, Propionibacterium, yeast, Leuconostoc, and Lactococcus. ## Claims ### Claim 1 A method for promoting secretion or suppressing decrease of adiponectin in a subject exhibiting metabolic syndrome, said method comprising: administering an effective amount of a first culture supernatant of Kluyveromyces lactis or Kluyveromyces marxianus or a second culture supernatant of Propionibacterium, as an active ingredient to a subject in recognized need of promoted secretion or suppressed decrease of adiponectin, who is a subject exhibiting metabolic syndrome; and promoting secretion or suppressing decrease of adiponectin in the subject. ### Claim 2 A method for accelerating the increase in or suppressing the decrease of adiponectin concentration, said method comprising: administering an effective amount of a culture supernatant of a microorganism selected from the group consisting of: Propionibacterium freudenreichii T004406 (CNCM I-3931), Propionibacterium freudenreichii subsp. freudenreichii DSM-20271T, and Propionibacterium freudenreichii subsp. shermanii DSM-4902T as an active ingredient to a subject in recognized need of accelerated increase in or suppressed decrease of adiponectin concentration; and accelerating the increase in or suppressing the decrease of adiponectin concentration in the subject. ### Claim 3 A method for accelerating the increase in or suppressing the decrease of adiponectin concentration, said method comprising: administering an effective amount of a culture supernatant of a microorganism selected from the group consisting of: Propionibacterium freudenreichii T004406 (CNCM I-3931), Kluyveromyces lactis T001985 (CNCM I-3935), Propionibacterium freudenreichii subsp. freudenreichii DSM-20271T, Kluyveromyces lactis NBRC-1090T, Propionibacterium freudenreichii subsp. shermanii DSM-4902T, and Kluyveromyces marxianus JCM-1630T, as an active ingredient to a subject in recognized need of accelerated increase in or suppressed decrease of adiponectin concentration; and accelerating the increase in or suppressing the decrease of adiponectin concentration in the subject. ### Claim 4 A method for promoting secretion or suppressing decrease of adiponectin, said method comprising: administering an effective amount of a culture supernatant of a microorganism selected from the group consisting of: Propionibacterium freudenreichii T004406 (CNCM I-3931), Kluyveromyces lactis T001985 (CNCM I-3935), Propionibacterium freudenreichii subsp. freudenreichii DSM-20271T, Kluyveromyces lactis NBRC-1090T, Propionibacterium freudenreichii subsp. shermanii DSM-4902T, and Kluyveromyces marxianus JCM-1630T, as an active ingredient to a subject in recognized need of promoted secretion or suppressed decrease of adiponectin; and promoting secretion or suppressing decrease of adiponectin concentration in the subject. ### Claim 5 A method for promoting secretion or suppressing decrease of adiponectin, said method comprising: administering an effective amount of a culture supernatant of a microorganism selected from the group consisting of: Propionibacterium freudenreichii T004406 (CNCM I-3931), Propionibacterium freudenreichii subsp. freudenreichii DSM-20271T, and Propionibacterium freudenreichii subsp. shermanii DSM-4902T as an active ingredient to a subject in recognized need of promoted secretion or suppressed decrease of adiponectin; and promoting secretion or suppressing decrease of adiponectin in the subject. ### Claim 6 (depends on 1) The method of claim 1, wherein the first or second culture supernatant is in dry or powder form. ### Claim 7 (depends on 1) The method according to claim 1, said method comprising administering an effective amount of a culture supernatant of Kluyveromyces lactis T001985 (CNCM I-3935), Kluyveromyces lactis NBRC-1090T, or Kluyveromyces marxianus JCM-1630T as an active ingredient.